Are scintigraphic esophageal transit studies necessary to detect the potential for esophageal injury of new drugs?
Weihrauch
T R
TR
Pharmaceutical Research Center, Bayer AG, Wuppertal.
D000368:Aged; D002214:Capsules / Q000009:adverse effects / Q000493:pharmacokinetics*; D004947:Esophagus / Q000000981:diagnostic imaging / Q000293:injuries* / Q000503:physiopathology; D005260:Female; D015902:Gamma Cameras; D005772:Gastrointestinal Transit / Q000502:physiology*; D005780:Gelatin; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011877:Radionuclide Imaging; D013608:Tablets, Enteric-Coated / Q000009:adverse effects / Q000493:pharmacokinetics*
D002214:Capsules; D013608:Tablets, Enteric-Coated; D005780:Gelatin